The recent surge in funding into specialized pharmaceutical companies, particularly those focusing on experimental therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for revolutionary treatments and substantial returns is clear, the connected risks are also significa… Read More